8,045 Shares in Pfizer Inc. (NYSE:PFE) Bought by Legacy Capital Wealth Partners LLC

Legacy Capital Wealth Partners LLC purchased a new stake in Pfizer Inc. (NYSE:PFE) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 8,045 shares of the biopharmaceutical company’s stock, valued at approximately $233,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. LGT Group Foundation grew its position in Pfizer by 2.5% in the second quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock valued at $20,786,000 after acquiring an additional 18,274 shares during the last quarter. Radnor Capital Management LLC acquired a new position in shares of Pfizer during the third quarter worth $2,972,000. Kornitzer Capital Management Inc. KS grew its position in shares of Pfizer by 2.4% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 1,168,315 shares of the biopharmaceutical company’s stock valued at $33,811,000 after buying an additional 27,562 shares during the last quarter. Capital Advisors Inc. OK increased its position in Pfizer by 3.5% during the 3rd quarter. Capital Advisors Inc. OK now owns 1,439,745 shares of the biopharmaceutical company’s stock valued at $41,666,000 after purchasing an additional 48,314 shares during the period. Finally, Costello Asset Management INC lifted its position in shares of Pfizer by 461.9% in the 3rd quarter. Costello Asset Management INC now owns 56,925 shares of the biopharmaceutical company’s stock worth $1,647,000 after purchasing an additional 46,795 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insiders Place Their Bets

In related news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. This represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Pfizer Stock Down 1.8 %

NYSE:PFE opened at $26.24 on Tuesday. The company has a market capitalization of $148.70 billion, a PE ratio of 35.46, a P/E/G ratio of 0.85 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.60. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $31.54. The firm’s 50-day moving average price is $28.89 and its 200-day moving average price is $28.67.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. During the same period in the prior year, the company posted ($0.17) earnings per share. The company’s quarterly revenue was up 31.2% on a year-over-year basis. On average, equities analysts predict that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 6.40%. The ex-dividend date is Friday, November 8th. Pfizer’s payout ratio is currently 227.03%.

Analyst Ratings Changes

Several research analysts have recently weighed in on PFE shares. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. UBS Group boosted their target price on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. Sanford C. Bernstein began coverage on Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective for the company. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. Eight analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and an average target price of $33.58.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.